Wall Street brokerages expect that Crispr Therapeutics AG (NASDAQ:CRSP) will post $59.43 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Crispr Therapeutics’ earnings. The highest sales estimate is $76.70 million and the lowest is $14.30 million. Crispr Therapeutics reported sales of $120,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 49,425%. The firm is expected to report its next earnings results on Monday, February 24th.

On average, analysts expect that Crispr Therapeutics will report full-year sales of $272.00 million for the current year, with estimates ranging from $226.90 million to $289.27 million. For the next fiscal year, analysts anticipate that the company will report sales of $30.04 million, with estimates ranging from $2.03 million to $58.10 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million.

Several equities research analysts recently weighed in on the company. Oppenheimer lifted their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, November 25th. Goldman Sachs Group increased their price objective on Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a report on Tuesday, November 19th. TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a research report on Monday, October 28th. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a report on Tuesday, November 19th. Finally, William Blair raised shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $69.54.

In related news, President Rodger Novak sold 33,618 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at $390,000. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock valued at $3,620,760 over the last 90 days. Corporate insiders own 21.40% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Benjamin Edwards Inc. grew its holdings in shares of Crispr Therapeutics by 96.4% during the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after buying an additional 268 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Crispr Therapeutics by 13.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock valued at $118,000 after purchasing an additional 343 shares during the last quarter. Traynor Capital Management Inc. boosted its stake in Crispr Therapeutics by 5.8% during the 3rd quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock valued at $280,000 after purchasing an additional 375 shares during the last quarter. Commonwealth Equity Services LLC increased its holdings in shares of Crispr Therapeutics by 2.2% in the 3rd quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock worth $746,000 after purchasing an additional 386 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. increased its holdings in shares of Crispr Therapeutics by 7.1% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock worth $331,000 after purchasing an additional 467 shares in the last quarter. Hedge funds and other institutional investors own 49.81% of the company’s stock.

Shares of NASDAQ:CRSP opened at $73.13 on Wednesday. The firm has a market capitalization of $4.04 billion, a P/E ratio of -21.26 and a beta of 3.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The stock has a 50 day moving average price of $52.76 and a 200-day moving average price of $46.89. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $74.00.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: Initial Public Offering (IPO)

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)



Source link